Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

ENDRA Life Sciences Inc

NDRA:NAQ

ENDRA Life Sciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2153
  • Today's Change0.018 / 9.29%
  • Shares traded344.00
  • 1 Year change-99.60%
  • Beta0.8085
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

  • Revenue in USD (TTM)0.00
  • Net income in USD-9.57m
  • Incorporated2007
  • Employees21.00
  • Location
    ENDRA Life Sciences Inc3600 Green Ct Ste 350ANN ARBOR 48105-2440United StatesUSA
  • Phone+1 (734) 335-0468
  • Fax+1 (302) 655-5049
  • Websitehttps://www.endrainc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Halberd Corp281.24k25.34k3.62m3.002.46--142.8712.890.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
NovaBay Pharmaceuticals Inc12.02m-15.98m3.65m24.00------0.3036-65.73-65.9121.94-0.45771.212.297.59500,958.30-105.75-61.51-205.52-83.8958.5559.99-87.67-86.470.4302--8.81--2.243.32-2.66---15.46--
Ainos Inc65.12k-15.41m3.78m46.00--0.1677--58.07-3.17-3.170.01262.800.00190.781413.861,415.65-44.29-36.36-49.13-58.33-316.6236.82-23,664.28-813.631.45-55.500.4016---96.539.461.69--66.44--
ENDRA Life Sciences Inc0.00-9.57m3.91m21.00--0.0347-----45.63-45.630.006.210.00----0.00-97.17-132.00-117.34-157.28------------0.00------23.67---19.46--
ProtoKinetix, Inc.0.00-369.97k3.99m0.00--9.83-----0.0011-0.00110.000.00120.00-------78.67-696.88-85.20-785.51------------0.00------78.22--10.78--
Creative Medical Technology Holdings Inc17.00k-5.73m4.00m4.00--0.5255--235.35-4.07-4.070.0125.690.00151.00--4,250.00-51.83-110.00-53.71--60.0065.82-33,716.41-7,961.1420.20--0.00---89.84-40.8647.88------
Helix BioMedix, Inc.2.07m-2.58m4.04m8.00--2.59--1.96-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Oragenics Inc7.47k-19.52m4.05m5.00------541.92-6.99-6.990.00230.23770.0013----1,494.00-349.31-97.60-451.26-106.24-----261,261.60-36,169.75----0.00---71.37---44.56--51.64--
Palisade Bio Inc0.00-14.17m4.07m9.00--0.3342-----20.07-20.070.0010.300.00----0.00-90.97-132.36-109.07-165.45-------27,892.32---972.730.0339-----0.781413.74--18.53--
Azitra Inc408.20k-9.96m4.08m10.00--0.2976--9.99-12.12-12.120.11511.800.0595--1.8340,820.00-145.30---194.72-------2,440.46------0.0191--141.55--6.02------
Synaptogenix Inc0.00-3.45m4.09m5.00--0.2075-----3.89-3.890.0014.990.00----0.00-5.54-40.33-6.89-43.36------------0.00-------142.17---3.21--
Enveric Biosciences Inc0.00-10.59m4.10m7.00--0.6705-----3.67-3.670.000.68620.00----0.00-133.67-104.94-206.10-156.88-------243.54----0.00------7.14------
Hepion Pharmaceuticals Inc0.00-28.37m4.13m22.00--2.21-----6.49-6.490.000.61420.00----0.00-133.45-61.43-167.53-68.82------------0.00-------7.92------
Lixte Biotechnology Holdings Inc0.00-4.03m4.14m3.00---------1.83-1.830.000.99860.00----0.00-139.98-104.18-163.33-111.05-----------563.880.00------19.41------
Peak Bio Inc354.02k-4.63m4.16m--------11.76-0.2066-0.20660.0135-0.97690.2192-------286.54-----------1,307.11-----4.85-----39.46--2.01------
Data as of Sep 23 2024. Currency figures normalised to ENDRA Life Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

3.65%Per cent of shares held by top holders
HolderShares% Held
S.H.N. Financial Investments Ltd.as of 04 Jun 20241.20m1.65%
L1 Capital Global, Inc.as of 04 Jun 20241.20m1.65%
Geode Capital Management LLCas of 30 Jun 202476.17k0.11%
Two Sigma Securities LLCas of 31 Mar 202447.91k0.07%
The Vanguard Group, Inc.as of 31 Mar 202439.81k0.06%
Jane Street Capital LLCas of 31 Mar 202436.12k0.05%
NewEdge Advisors LLCas of 31 Mar 202430.94k0.04%
XTX Markets LLCas of 31 Mar 202410.76k0.02%
Tower Research Capital LLCas of 31 Mar 20248.66k0.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024332.000.00%
More ▼
Data from 31 Mar 2024 - 25 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.